查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1526338

全球生物可吸收支架市场

Bioresorbable Stents
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 125 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计2030年全球生物可吸收支架市场将达12亿美元

2023年全球生物可吸收支架市场估计为5.544亿美元，预计到2030年将达到12亿美元，2023-2030年分析期间复合年增长率为12.1%。聚合物生物可吸收支架是本报告分析的细分市场之一，预计复合年增长率为 12.8%，到分析期结束时将达到 9.052 亿美元。分析期间，金属基生物可吸收支架细分市场的复合年增长率预计为 10.2%。

全球生物可吸收支架市场趋势及驱动因素总结

生物可吸收支架，也称为生物可吸收血管支架（BVS），代表了介入性心臟病学的重要进步。这些支架旨在手术后暂时支撑动脉，并随着时间的推移逐渐溶解，留下天然血管。与永久留在体内的传统金属支架不同，生物可吸收支架由聚乳酸（PLA）等材料製成，可自然分解并被人体吸收。这种暂时性降低了与永久植入相关的长期风险，例如慢性发炎和晚期血栓症。临床试验表明，生物可吸收支架可有效治疗冠状动脉疾病，其效果与金属支架相当，并且随着时间的推移恢復血管的自然功能和灵活性也有优势。

广泛的研究和创新推动了生物可吸收支架的发展。这些支架旨在在血管成形术后的关键癒合期间为动脉提供必要的机械支撑。随着时间的推移，支架会逐渐劣化，从而降低长期併发症的风险。此外，生物可吸收支架通常会涂上抗增生药物，以进一步防止血管再阻塞或动脉血管再阻塞。机械支撑和药物输送的双重功能改善了患者的治疗效果。此外，先进影像处理技术和精密工程的使用改善了这些支架的部署和功效，使其成为更广泛的患者和临床环境的可行选择。

生物可吸收支架市场的成长受到多种因素的推动。首先，心血管疾病，特别是冠状动脉疾病的盛行率在全世界不断增加，需要有效和创新的治疗方案。其次，患者和医疗保健提供者对微创手术的需求不断增长，刺激了生物可吸收支架的采用。这些支架为传统方法提供了一种有前景的替代方案，并且符合微创干预的趋势。第三，生物材料和支架设计的技术进步提高了生物可吸收支架的性能和安全性，使其对临床医生更具吸引力。最后，患者对这些支架的认识和接受度不断提高，再加上多个地区有利的报销政策，正在进一步推动市场成长。这些因素共同支持生物可吸收支架在现代心血管治疗范例中不断扩大的作用。

受访企业范例（25家知名企业）

  • Abbott Laboratories, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Eurocor GmbH
  • Biosensors International Group Ltd.
  • Elixir Medical Corporation
  • InSitu Technologies, Inc.
  • Kyoto Medical Planning Co., Ltd.
  • Medinol Ltd.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Alvimedica Saglik Ekipmanlari Pazarlama Satis ve Dagitim AS
  • Meril Life Sciences Pvt., Ltd.
  • Arterial Remodeling Technologies SA
  • iVascular SLU
  • Endocor GmbH

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 世界市场概览
  • 市场展望
  • 竞赛
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 欧洲
  • 亚太地区
  • 世界其他地区

第四章 比赛

简介目录
Product Code: MCP10697

Global Bioresorbable Stents Market to Reach US$1.2 Billion by 2030

The global market for Bioresorbable Stents estimated at US$554.4 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2023-2030. Polymer-based Bioresorbable Stents, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$905.2 Million by the end of the analysis period. Growth in the Metal-based Bioresorbable Stents segment is estimated at 10.2% CAGR over the analysis period.

Global Bioresorbable Stents Market - Key Trends & Drivers Summarized

Bioresorbable stents, also known as bioresorbable vascular scaffolds (BVS), represent a significant advancement in interventional cardiology. These stents are designed to provide temporary support to the artery after a procedure, gradually dissolving over time and leaving behind a natural vessel. Unlike traditional metal stents, which remain permanently in the body, bioresorbable stents are composed of materials like polylactic acid (PLA) that naturally break down and are absorbed by the body. This temporary nature reduces the long-term risks associated with permanent implants, such as chronic inflammation and late-stage thrombosis. Clinical trials have demonstrated the efficacy of bioresorbable stents in treating coronary artery disease, showing comparable outcomes to metallic stents with the added benefit of restoring the vessel's natural function and flexibility over time.

The development of bioresorbable stents has been propelled by extensive research and technological innovations. These stents are engineered to provide the necessary mechanical support to the artery during the critical healing period post-angioplasty. Over time, the stent gradually degrades, reducing the risk of long-term complications. Additionally, bioresorbable stents are often coated with antiproliferative drugs to further prevent restenosis, or re-narrowing of the artery. This dual function of providing mechanical support and drug delivery enhances the therapeutic outcomes for patients. Furthermore, the use of advanced imaging techniques and precision engineering has improved the deployment and efficacy of these stents, making them a viable option for a broader range of patients and clinical scenarios.

The growth in the bioresorbable stents market is driven by several factors. Firstly, there is an increasing prevalence of cardiovascular diseases globally, particularly coronary artery disease, which necessitates effective and innovative treatment options. Secondly, the rising demand for minimally invasive procedures among patients and healthcare providers is fueling the adoption of bioresorbable stents. These stents offer a promising alternative to traditional methods, aligning with the trend towards less invasive interventions. Thirdly, technological advancements in biomaterials and stent design are enhancing the performance and safety profile of bioresorbable stents, making them more attractive to clinicians. Lastly, the growing awareness and acceptance of these stents among patients, coupled with favorable reimbursement policies in several regions, are further boosting market growth. The confluence of these factors underscores the expanding role of bioresorbable stents in modern cardiovascular treatment paradigms.

Select Competitors (Total 25 Featured) -

  • Abbott Laboratories, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Eurocor GmbH
  • Biosensors International Group Ltd.
  • Elixir Medical Corporation
  • InSitu Technologies, Inc.
  • Kyoto Medical Planning Co., Ltd.
  • Medinol Ltd.
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Alvimedica Saglik Ekipmanlari Pazarlama Satis ve Dagitim A.S.
  • Meril Life Sciences Pvt., Ltd.
  • Arterial Remodeling Technologies SA
  • iVascular S.L.U
  • Endocor GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Bioresorbable Stents - Global Key Competitors Percentage Market Share in 2024 (E)
    • Coronary Artery Disease (CAD) - A Perspective
    • Causes and Symptoms
    • Treatment Options for Coronary Artery Disease
    • Percutaneous Coronary Intervention (PCI)
    • Coronary Stenting
    • Types of Coronary Stents
    • Bare Metal Stents (BMS)
    • Drug Eluting Stents (DES)
    • Bioresorbable Scaffolds
    • Design and Composition of Bioresorbable Scaffolds
    • Different Types of Bioresorbable Scaffolds
    • Metallic Bioresorbable Scaffolds
    • Polymer Bioresorbable Scaffolds
    • Degradation Period of Select Bioabsorbable Materials
    • Challenges
    • Clinical Characteristics of Various Coronary Stents
    • Other Treatment Options for Coronary Heart Disease
    • Coronary Artery Bypass Grafting (CABG)
    • Minimally Invasive Direct Coronary Artery Bypass (MIDCAB)
    • TransMyocardial Laser Revascularization (TMR)
    • Peripheral Arterial Disease: Understanding the Stealthy Peril
    • Treatment for PAD
    • Stenting- A Treatment Option for PAD
    • BioResorbable Stents - A Prelude
    • Bioresorbable Vascular Scaffolds: Advantages and Challenges
    • Bioresorbable Stents - A Revolutionary Technology, Riddled with Controversies
    • Abbott Stops Sales of the Once Promising 'Absorb' Bioresorbable Stents due to Adverse Events
    • Impact of Abbott's Withdrawal of Absorb on the Bioresorbable Stent Industry
  • GLOBAL MARKET OVERVIEW
    • Global Bioresorbable Stents Set to Witness Growth in Future
    • Europe Dominates, Asia-Pacific Exhibits Fastest Growth
    • CAD Constitutes the Leading Application
    • Metallic Vs. Polymer-based Stents
    • Bioabsorbable Metallic Stents
    • Bioabsorbable Polymer Stents
    • Disappointing Results by Absorb to Increase Focus on Metallic Stents
    • Availability of Alternative Treatments - Hindrance to Market Growth
    • Market Challenges
  • MARKET OUTLOOK
    • Bioresorbable and Integrated Biosensor Technology to Redefine Future of Vascular Stents
    • The Future of BRS Technology
  • COMPETITION
    • Select Approved Bioresorbable Scaffolds
    • Select Bioresorbable Stents in Pipeline
    • Abbott Revives Bioresorbable Stent Clinical Trials to Evaluate New Esprit Scaffold
    • Recent Market Activity
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Polymeric Resorbable Scaffolds Hold a Major Market Share
    • The Absorb BRS program
    • Desaminotyrosine Polycarbonate-based BRS
    • The FANTOM program
    • Magnesium-based BRS
    • The Magmaris program
    • Iron-based BRS
    • Global Menace of Coronary Artery Disease (CAD) - A Major Growth Driver
    • Global Annual Medical Cost of CVD in the United States: 2015-2030
    • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Ageing Demographics and Longer Life Expectancy Bolsters Market Growth
    • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Rising Middle Class Population Aids Growth
    • Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P
    • Rising Healthcare Expenditure: Opportunities in Store
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Risk of CAD in Obesity Offers Prospects for Coronary Stenting
    • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Diabetics at Higher Risk of Heart Diseases
    • TABLE 15: Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years) with Diabetes in 2015 and 2040
    • The Hypertension-Cholesterol Link to Drive Demand
    • Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years
    • Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer Stents
    • Metal Stents Vis-a-Vis Other Stents
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Bioresorbable Stents by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Bioresorbable Stents by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Polymer-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Polymer-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Metal-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Metal-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Coronary Artery Disease/CAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for Coronary Artery Disease/CAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Peripheral Artery Disease/PAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Peripheral Artery Disease/PAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cardiovascular Centers by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World 7-Year Perspective for Cardiovascular Centers by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 15: World Bioresorbable Stents Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030

III. MARKET ANALYSIS

  • EUROPE
    • Bioresorbable Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 16: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 17: Europe 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2024 & 2030
    • TABLE 18: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Europe 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2024 & 2030
    • TABLE 20: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Europe 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Bioresorbable Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 22: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2024 & 2030
    • TABLE 24: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2024 & 2030
    • TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Asia-Pacific 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 28: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of World 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2024 & 2030
    • TABLE 30: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Rest of World 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2024 & 2030
    • TABLE 32: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Rest of World 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2024 & 2030

IV. COMPETITION